SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

9776	Companies
195668	Keywords
126689	Articles
104037	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 10/17/2025 at 13:00, 3 months 13 days ago

Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
Sanofi announces negative CHMP opinion on Rezurock for chronic graft-vs-host disease in the EU but plans to seek re-examination. Rezurock has shown efficacy in clinical studies

EU Sanofi CHMP Rezurock CGVHD
BRIEF

published on 10/08/2025 at 07:05, 3 months 22 days ago

AlphaMedixTM: Positive Phase 2 Results for the Treatment of GEP-NETs

Clinical Trial Phase 2 Innovative Therapy AlphaMedixTM TNE-GEP
BRIEF

published on 09/24/2025 at 07:10, 4 months 6 days ago

Sanofi invests $625 million to boost Sanofi Ventures

Innovation Digital Health Investment Sanofi Biotechnologies
PRESS RELEASE

published on 09/24/2025 at 07:05, 4 months 6 days ago

Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Sanofi commits $625 million to Sanofi Ventures to boost biotech and digital health investments. Focus on immunology, rare diseases, neurology, vaccines

Digital Health Investment Biotech Ventures Sanofi
BRIEF

published on 09/24/2025 at 07:05, 4 months 6 days ago

Sanofi Releases Q3 2025 Aide Mémoire

Investor Relations Sanofi Financial Modeling Results Announcement Q3 2025
PRESS RELEASE

published on 09/24/2025 at 07:00, 4 months 6 days ago

Press release: Availability of the Q3 2025 Aide mémoire
Sanofi announces availability of Q3 2025 Aide mémoire for financial modeling purposes. Document covers non-comparable items, foreign currency impact, and share count

Investors Sanofi Financial Modeling Aide Mémoire Q3 2025
BRIEF

published on 09/23/2025 at 07:05, 4 months 7 days ago

Sanofi's SAR446268 Therapy Advances in the United States

Gene Therapy Sanofi SAR446268 FDA Admission Myotonic Dystrophy
PRESS RELEASE

published on 09/23/2025 at 07:00, 4 months 7 days ago

Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Sanofi's SAR446268 granted US fast track designation for non-congenital myotonic dystrophy type 1. AAV gene therapy aims to silence DMPK expression, addressing symptoms and filling unmet need

AAV Gene Therapy Sanofi Fast Track Designation SAR446268 Myotonic Dystrophy Type 1
BRIEF

published on 09/17/2025 at 07:05, 4 months 13 days ago

Sanofi's Brivekimig Shows Promise in Hidradenitis Suppurativa Treatment

Brivekimig Hidradenitis Suppurativa Phase 2a Study Nanobody Technology Immune-mediated Diseases
PRESS RELEASE

published on 09/17/2025 at 07:00, 4 months 13 days ago

Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Sanofi's brivekimig shows positive results in phase 2a study for hidradenitis suppurativa, presenting clinically meaningful improvements in primary and secondary endpoints in biologic-naïve patients

Sanofi Brivekimig Hidradenitis Suppurativa Phase 2a Study Immune-mediated Diseases

Accesswire

Published on 01/30/2026 at 14:00, 4 hours 12 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 9 hours 37 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 10 hours 12 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 15 hours 57 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 18 hours 12 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

EQS Group

Published on 01/30/2026 at 17:55, 16 minutes ago

Wellington College International to Open First African School in Alaro City, Lagos in 2027
Published on 01/30/2026 at 17:29, 43 minutes ago

EQS-Adhoc: The Payments Group Holding GmbH & Co. KGaA: The Payments Group Holding – Successful issuance of convertible bond
Published on 01/30/2026 at 17:09, 1 hour 3 minutes ago

Halfords Group PLC: Total Voting Rights
Published on 01/30/2026 at 16:54, 1 hour 17 minutes ago

Holding(s) in Company
Published on 01/30/2026 at 16:46, 1 hour 25 minutes ago

Custodian Property Income REIT plc: Investor Presentation via Investor Meet Company

Les Echos

Published on 01/30/2026 at 17:45, 27 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 10 hours 12 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE